Bausch + Lomb Corporation
HealthcareNYSE:BLCO · New York Stock Exchange
-$0.20 today
Vol 0.23M · Avg 0.47M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $268.0M |
| Receivables | $1.1B |
| Inventory | $977.0M |
| Other Current | $425.0M |
| Total Current Assets | $2.8B |
| PP&E (Net) | $1.8B |
| Goodwill | $4.7B |
| Intangible Assets | $3.2B |
| Tax Assets | $945.0M |
| Other Non-current | $302.0M |
| Total Non-current Assets | $11.0B |
| Total Assets | $13.8B |
Analysis
Selected assets total $13.8B for Latest. The largest visible component is Goodwill at $4.7B, about 34.4% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $383.0M +25.6% | $305.0M -8.7% | $334.0M -12.1% | $380.0M +118.4% | $174.0M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $0 | $0 | $0 | $0 | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $1.2B +19.0% | $1.0B +17.3% | $875.0M +20.5% | $726.0M +0.7% | $721.0M | $533.8M | $399.4M | -$1.7B |
| Inventory | $976.0M -5.8% | $1.0B +0.8% | $1.0B +63.7% | $628.0M +9.8% | $572.0M | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $397.0M -5.7% | $421.0M -16.6% | $505.0M +25.3% | $403.0M +13333.3% | $3.0M | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $3.0B +6.8% | $2.8B +1.7% | $2.7B +28.3% | $2.1B +30.7% | $1.6B | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $1.8B +18.7% | $1.5B -1.3% | $1.5B +6.0% | $1.4B +6.1% | $1.3B | $1.2B | $1.5B | $687.8M |
| Goodwill | $4.8B +5.2% | $4.5B -1.1% | $4.6B +1.5% | $4.5B -1.7% | $4.6B | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $3.3B -6.1% | $3.5B -2.6% | $3.6B +74.4% | $2.1B -9.1% | $2.3B | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $7.0M -63.2% | $19.0M +0.0% | $19.0M +58.3% | $12.0M | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $934.0M +5.5% | $885.0M -3.9% | $921.0M -0.6% | $927.0M | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $303.0M +10.2% | $275.0M +198.9% | $92.0M +9.5% | $84.0M -91.6% | $1.0B | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $11.0B +3.4% | $10.7B -0.2% | $10.7B +18.8% | $9.0B -2.0% | $9.2B | -$15.3B | $14.8B | $11.3B |
| Total Assets | $14.0B +4.1% | $13.5B +0.2% | $13.4B +20.6% | $11.1B +3.0% | $10.8B | $13.3B | $11.9B | $10.6B |
| Account Payables | $388.0M -0.3% | $389.0M -25.5% | $522.0M +64.7% | $317.0M +32.6% | $239.0M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $77.0M +92.5% | $40.0M -29.8% | $57.0M +11.8% | $51.0M +82.1% | $28.0M | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $1.5B +13.9% | $1.3B +80.1% | $709.0M -3.1% | $732.0M +105.6% | $356.0M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $1.9B +10.5% | $1.7B +10.1% | $1.6B +21.8% | $1.3B +17.9% | $1.1B | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $5.2B +8.9% | $4.7B +4.7% | $4.5B +88.0% | $2.4B | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $19.0M +46.2% | $13.0M -7.1% | $14.0M +100.0% | $7.0M | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $271.0M -12.6% | $310.0M +0.0% | $310.0M +30.8% | $237.0M +3.0% | $230.0M | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $5.6B +7.6% | $5.2B +4.9% | $4.9B +79.9% | $2.7B +753.1% | $322.0M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $7.5B +8.3% | $6.9B +6.2% | $6.5B +61.3% | $4.0B +184.5% | $1.4B | $14.7B | $3.7B | $9.6B |
| Common Stock | $0 | $0 | $0 | $0 -100.0% | $10.4B | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$931.0M -63.0% | -$571.0M -124.8% | -$254.0M -4333.3% | $6.0M | $0 | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | -$1.2B +14.5% | -$1.4B -11.2% | -$1.2B +1.0% | -$1.3B -21.5% | -$1.0B | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $71.0M +0.0% | $71.0M +1.4% | $70.0M +2.9% | $68.0M -6.8% | $73.0M | $1.4B | $337.8M | $931.4M |
| Total Equity | $6.5B -0.4% | $6.5B -5.4% | $6.9B -2.5% | $7.1B -24.5% | $9.4B | $9.1B | $7.7B | $3.3B |
| Total Debt | $5.4B +8.8% | $4.9B +5.6% | $4.7B +83.1% | $2.6B +1724.3% | $140.0M | $724.2M | $410.6M | $399.4M |
| Net Debt | $5.0B +7.7% | $4.6B +6.7% | $4.3B +99.7% | $2.2B +6494.1% | -$34.0M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWR
$10.48B
TG Therapeutics, Inc.
NASDAQ:TGTX
$7.59B
Glaukos Corporation
NYSE:GKOS
$7.45B
Oscar Health, Inc.
NYSE:OSCR
$7.31B
Vaxcyte, Inc.
NASDAQ:PCVX
$6.87B
Arcellx, Inc.
ACLX
$6.73B
PTC Therapeutics, Inc.
NASDAQ:PTCT
$6.23B
Teleflex Incorporated
NYSE:TFX
$5.78B
CRISPR Therapeutics AG
NASDAQ:CRSP
$4.82B
Merit Medical Systems, Inc.
NASDAQ:MMSI
$3.98B
SEC Filings
Recent regulatory filings
No filings found.
How much cash does BLCO have?
Bausch + Lomb Corporation (BLCO) reported $383.00M in cash and equivalents in fiscal 2025.
How much debt does BLCO carry?
Bausch + Lomb Corporation (BLCO) reported $5.37B of total debt, with net debt of $4.99B.
Explore More
Continue the stock analysis
Jump to another research area for this company.